Human immunodeficiency virus type 1 antigens (delivered by Modified Vaccinia Ankara 62B) (MVA-B)

HIV-1 antigens delivered by MVA62B represent a specific antigenic payload used in the development of HIV vaccines, most notably the MVA-B candidate (García et al., 2011, Vaccine). The MVA62B vector is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus engineered to express three major HIV-1 clade B proteins: Gag, Pol, and Env (Gómez et al., 2011, Journal of Virology). These proteins are processed and presented by the host's cells to stimulate both the cellular and humoral arms of the immune system. Specifically, the Gag and Pol antigens are designed to elicit robust CD8+ cytotoxic T-lymphocyte responses, while the Env protein aims to induce neutralizing antibodies (Guardo et al., 2017, Expert Review of Vaccines). This target is primarily utilized in prime-boost vaccination strategies, where it often serves as a boost following a DNA vaccine prime to enhance the magnitude and durability of the immune response (NCT00637117). Clinical studies have demonstrated that this approach can induce polyfunctional T-cell responses in both healthy volunteers and HIV-infected individuals under antiretroviral therapy. The ultimate goal of targeting these antigens via the MVA62B delivery system is to provide long-term protection against HIV-1 infection or to achieve functional cure by controlling viral replication.

Other names

MVA-BMVA62BHIV-1 Gag-Pol-Env (clade B)Recombinant MVA-HIV-1 clade B

Induction of HIV-specific cellular and humoral immune responses through viral vector-mediated antigen expression and presentation.